Prof. Gilles Salles | EBMT 2018 | Emerging CAR T-cell therapy in Lymphoma

L: English
Watch French version

  • Professor Salles discusses CAR-T developments in lymphoma starting with the onset of CAR-T trials in 2017 that will continue into 2018.
  • He explained that early results showed that very refractory patients this single infusions treatment can produce a high response rate from 50% up to 85% with 40% achieving complete remission.
  • CAR-T therapy involves a multidisciplinary team effort in order to deliver it efficiently and safely to patients and he added that it will be interesting to see where this therapy will fit into standard care in the future.
44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, PT.
Professor Gilles Salles, South Lyon University Hospital Complex, Lyon, FR
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF